Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Specify a stock or a cryptocurrency in the search bar to get a summary
Internet Computer
ICP
Bitcoin Cash
BCH
Litecoin
LTC
Imunon Inc
CBOCurrent price
0.84 EUR
+0.015 EUR (+1.82%)
Last closed
0.93 USD
Company
celsion.com
ISIN
unknown
Sector
Healthcare
Industry
Biotechnology
Exchange
Frankfurt Exchange
Capitalization
13 582 959 USD
Yield for 12 month
-7.77 %
1Y
3Y
5Y
10Y
15Y
CBO
Imunon, Inc., a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company's lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development. Its preclinical stage products include IMNN-101, a COVID-19 booster vaccine; IMNN-102 for the treatment of Lassa virus; and IMNN-201, a Trp2 tumor associated antigen cancer vaccine in melanoma. In addition, the company develops non-viral DNA technology across four modalities, such as TheraPlas for the coding of proteins and cytokines in the treatment of solid tumors; PlaCCine for the coding of viral antigens that can elicit a strong immunological response; FixPlas for the application of Imunon's DNA technology to produce universal cancer vaccines; and IndiPlas, which is in the discovery phase for the development of personalized cancer vaccines or neoepitope cancer vaccines. Imunon, Inc. was formerly known as Celsion Corporation and changed its name to Imunon, Inc. in September 2022. The company was founded in 1982 and is headquartered in Lawrenceville, New Jersey. Address: 997 Lenox Drive, Lawrenceville, NJ, United States, 08648
Check your investment idea
Find the best to beat the market
TSLA
Tesla Motors
AAPL
Apple
MSFT
Microsoft
Analytics
WallStreet Target Price
14.2 USDP/E ratio
–Dividend Yield
–Current Year
+125 000 USD
Last Year
+500 000 USD
Current Quarter
–
Last Quarter
–
Current Year
-720 005 USD
Last Year
-231 629 USD
Current Quarter
-185 270 USD
Last Quarter
-178 310 USD
Key Figures CBO
1 year
3 years
5 years
10 years
EBITDA
-19 618 188 USD
Operating Margin TTM
PE Ratio
–
Return On Assets TTM
-64.75 %
PEG Ratio
–
Return On Equity TTM
-143.19 %
Wall Street Target Price
14.2 USD
Revenue TTM
125 000 USD
Book Value
0.4 USD
Revenue Per Share TTM
Dividend Share
–
Quarterly Revenue Growth YOY
–
Dividend Yield
–
Gross Profit TTM
500 000 USD
Earnings per share
-1.91 USD
Diluted Eps TTM
-1.91 USD
Most Recent Quarter
II 2024
Quarterly Earnings Growth YOY
–
Profit Margin
–
Dividend Analytics CBO
Dividend growth over 5 years
–Continuous growth
–Payout Ratio 5 years average
–Dividend History CBO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
–
Ex Dividend Date
–
Forward Annual Dividend Yield
–
Last Split Factor
1:15
Payout Ratio
–
Last Split Date
01.03.2022
Dividend Date
–
Stock Valuation CBO
1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
–
Forward PE
–
Enterprise Value Revenue
4.0043
Price Sales TTM
17.9405
Enterprise Value EBITDA
0.9097
Price Book MRQ
3.5702
Financials CBO
1 year
3 years
5 years
10 years
15 years
| Results | 2019 | Dynamics |
* The data for this period has not yet been published
Technical indicators CBO
For 52 weeks
0.48 USD
3.65 USD
50 Day MA
1.07 USD
Shares Short Prior Month
432 348
200 Day MA
1.11 USD
Short Ratio
1.5
Shares Short
337 569
Short Percent
2.35 %
BeatStart